

2024 Area of Interest for Pulmonary Hypertension

Effective February 2024, the Investigator Studies Program Review Committee (MISP-RC) for Pulmonary Hypertension will accept submissions within our current Areas of Interest (Aols) below. Decisions will be made on the basis of scientific merit and strategic fit within the Aols (which are subject to change).

The following areas are of interest to the Investigator Studies Program Review Committee:

Pulmonary Hypertension (Sotatercept)

- Investigation of the molecular mechanisms through which sotatercept exerts its biological effects and regulates PAH
- Characterization of pulmonary vascular remodeling / reverse remodeling +/- effect of sotatercept
- Impact of activin signaling inhibition on pulmonary vasculature and/or right ventricle +/- Imaging and/or physiologic changes with sotatercept
- Effect of sotatercept in select PAH subgroups/disease severity/background therapies

※申し込みは受け付けますが、研究の開始時期については別途お問合せください。